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Abstract
Background: Prognosis among patients with differentiated thyroid cancer is widely 
variable. Better understanding of biologic subtypes is necessary to stratify patients 
and improve outcomes.
Methods: In patients diagnosed with classic histology papillary thyroid cancer 
treated from 1973 to 2009, BRAF V600E mutation status was determined on surgical 
tumor specimens by restriction fragment length polymorphism analysis. A tissue mi-
croarray (TMA) was constructed from tumor specimens in triplicate and stained by 
immunohistochemistry for RET, phospho‐MEK, MAPK(dpERK), PPARγ, and 
phospho‐AKT(pAKT). Stained slides were scored independently and blindly by two 
investigators and compared to tumor and patient characteristics and outcomes.
Results: A total of 231 patients had archived formalin‐fixed, paraffin‐embedded 
tumor tissue available and were included on the TMA. Mean age at diagnosis was 
44 years (range 6‐82 years); proportion of patients with female sex was (72%); 2015 
American Thyroid Association (ATA) risk stratification was low (26%), intermedi-
ate (32%), and high (42%). BRAF V600E mutation was found in 74% of specimens, 
and IHC was scored as positive for RET (61%), MAPK (dpERK) (14%), PPARγ 
(27%), and pAKT (39%). Positive RET staining was associated with a lower risk of 
recurrence (HR = 0.46, 95% CI 0.22‐0.96). No other molecular biomarkers were in-
dependent predictors of recurrence on univariable analysis. On RPA, patients with 
RET‐negative and either MAPK(dpERK)‐positive or pAKT‐positive tumors were 
identified to have a high risk of recurrence (HR = 5.4, 95%CI 2.5‐11.7). This profile 
remained associated with recurrence in a multivariable model including ATA risk 
stratification (HR = 2.8, 95% CI 1.3‐6.0).
Conclusion: Characterization of molecular pathways involved in cPTC tumorigen-
esis may add further risk stratification for recurrence beyond the 2015 ATA risk 
categories alone.
438 |   LIN et aL.
1 |  INTRODUCTION
Thyroid cancer represents the most common endocrine ma-
lignancy, accounting for an estimated 53 990 new diagno-
ses in the United States in 2018.1 Papillary thyroid cancers 
(PTC) account for 65%‐88% of all thyroid cancers.2 Post‐thy-
roidectomy pathological findings play an important role in 
prognosis, and along with patient age and total body iodine 
uptake scan, comprise the three‐tiered risk stratification sys-
tem endorsed in the American Thyroid Association (ATA) 
2015 guidelines to predict risk of recurrent disease.3 Rates of 
recurrence vary widely within risk groups,3 reflecting resid-
ual heterogeneity. Differences in tumor biology may explain 
much of the variability, and molecular markers of aggressive 
disease have been proposed to further stratify the three‐tiered 
risk system.
The proto‐oncogene BRAF V600E mutation has been 
extensively studied and characterized in the PTC literature, 
though with conflicting associations with recurrence in mul-
tiple studies. A pooled meta‐analysis of 14 studies including 
2470 PTC patients found BRAF mutation was associated with 
twice the risk of recurrence (24.9% vs 12.6%, P < 0.00001).4 
It is unclear whether BRAF mutation independently confers 
additional risk as it is often linked to aggressive histologi-
cal findings.5 Though BRAF mutation is quite prevalent 
(30%‐80%),6 even in the intermediate‐ and high‐risk groups, 
BRAF mutation alone is not consistently prognostic. In our 
prior institutional series of 508 PTC patients with 8‐year 
median follow‐up, nearly half of the patients had multifocal 
disease, extrathyroidal extension, and cervical nodes. BRAF 
V600E mutation was prevalent (67%), but was not associated 
with recurrence or disease‐specific survival.7 This suggests 
that additional molecular drivers may be responsible for ag-
gressive cPTC.
The Cancer Genome Atlas (TCGA) recently reported their 
analysis of 496 PTC samples and found significant genetic vari-
ation amongst the BRAF mutant cohort.8 In their analysis, two 
common oncogenic pathways were identified: (a) BRAF muta-
tion constitutively activating mitogen‐activated protein kinase 
kinase (MEK) and mitogen‐activated protein kinase (MAPK), 
and (b) RAS activating both PI3 kinase/phosphorylated AKT 
(pAKT) and the MAPK/Extracellular Signal‐Related Kinase 
(ERK) pathway. Upstream of either proposed pathway is the 
RET proto‐oncogene (RET). Downstream effects of cell pro-
liferation and dedifferentiation are thought to promote tumor 
growth, invasiveness, and resistance to radioactive iodine.8,9 
It is possible that genetic, transcriptional, or post‐translational 
regulation of factors along this pathway could have similar 
downstream effects even in the absence of upstream genetic 
activation. Therefore, we sought to characterize the molecular 
expression at the protein level of five factors along the BRAF 
and RAS pathways in a large single institution cohort of PTC 
patients with long clinical follow‐up. We sought to identify 
molecular signatures that may be associated with clinical 
outcomes.
2 |  METHODS
2.1 | Patient selection
Patients referred to Radiation Oncology from 1973 to 2009 
with a diagnosis of classic papillary histology thyroid cancer 
(cPTC) who underwent thyroidectomy and had available ar-
chived tumor specimens were included. Other histologic var-
iants of PTC, including follicular and tall cell variants, were 
specifically excluded. This retrospective study was approved 
by the institutional review board with waiver of consent.
2.2 | BRAF V600E mutation analysis
BRAF V600E mutation status was determined as previ-
ously published.7 Briefly, thyroid tumor specimens were 
unarchived from formalin‐fixed, paraffin‐embedded (FFPE) 
biopsies. Tissue slides stained with hematoxylin and eosin 
were examined and marked by a board certified pathologist 
(JP) to identify areas of cPTC. For BRAF mutation status, 
total RNA was isolated from two tissue cores of 1 mm di-
ameter and the BRAF exon was amplified with polymerase 
chain reaction (PCR). BRAF V600E mutation was identified 
with restriction fragment length polymorphism (RFLP) anal-
ysis, which has been previously validated.7
2.3 | Immunohistochemistry analysis
A tissue microarray (TMA) was constructed from the 
same FFPE samples. Areas of cancer were punched with 
1.5 mm cores and placed in triplicate into recipient blocks. 
IHC stains for RET (C‐19; Santa Cruz Biotechnology, 
Dallas, TX), phospho‐MEK (pMEK; 166F8; Cell 
Signaling Technology, Danvers, MA), phospho‐p44/42 
MAPK (dpERK; Erk1/2, Thr202/Tyr204, 20G11; Cell 
Signaling Technology), PPARγ (SC‐7273P; Santa Cruz 
Biotechnology), and phospho‐AKT (pAKT; Ser473, 
Thr308; Cell Signaling Technology) were scored indepen-
dently and blindly by two investigators on a scale of 0‐3 
for staining intensity and percentage of stain positive cells. 
K E Y W O R D S
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The initial scoring of 0 to 3 was chosen to better character-
ize the range of staining intensity/percent positive seen in 
the cohort. Examples of control slides staining and each 
score for the TMA are presented in Supplemental Figures 
S1 and S2, respectively. An average score of ≥2 was cat-
egorized as positive, as judged by either investigator, and 
<2 was categorized as negative. Concordance in scoring 
between both investigators was determined to document 
interpersonal scoring heterogeneity.
2.4 | Treatment and follow‐up
All patients underwent thyroidectomy. Post‐operative radio-
active iodine (RAI) was administered to 215 patients. Whole‐
body scans were typically performed post‐RAI ablation, and 
surveillance total body scans were performed after thyroid 
hormone withdrawal at 1 year following RAI. Non‐palpable 
persistent disease on the whole‐body scan was treated with ad-
ditional RAI. Surveillance consisted of physical examination 
and laboratory studies including thyroid stimulating hormone 
(TSH), triiodothyronine, and free thyroxine with the addi-
tion of thyroglobulin levels in the latter years of the study. 
Recurrence was defined as either positive disease found on the 
whole‐body scan in a previously negative area, positive dis-
ease seen on other clinical imaging (eg, neck ultrasound or CT 
scan), or pathologically proven recurrence. Metastatic patients 
who never responded to RAI and had continued progression 
of disease were also coded as recurrent at time of diagnosis.
2.5 | Statistics
Concordance of TMA scoring was evaluated with Cohen’s 
kappa,10 with a cutoff score above 0.4 required to be included 
in further analysis. Two‐tailed student’s t tests were used to 
compare continuous variables, and Fisher’s exact tests were 
used to compare categorical variables. Significant differ-
ences were considered if P < 0.05. Binary logistic regression 
was used to identify significant clinicopathologic factor as-
sociations with each molecular marker. Kaplan‐Meier and 
log‐rank tests were used for freedom from recurrence (FFR) 
and cancer‐specific survival (CSS). Univariable and multi-
variable Cox regression was used to model predictors of re-
currence and thyroid cancer death. Results were considered 
significant if the 95% confidence interval (CI) did not cross 
one.
In order to determine molecular risk classification, 
recursive partition analysis (RPA) was conducted for the 
outcome of disease utilizing survival trees. Pruning was 
completed, when necessary, by recursively snipping off 
the least important splits based on the complexity param-
eter (CP). All statistical analyses were done with R ver-
sion 3.03, SAS version 9.4, and SPSS, version 23 (IBM, 
Armonk, NY).
3 |  RESULTS
3.1 | Patients and treatments
A total of 1712 patients with a diagnosis of thyroid cancer 
were referred to our department from 1973 to 2009. A total 
of 383 patients with cPTC histology who underwent partial 
or total thyroidectomy had available tumor specimens. Of 
these patients, 244 had adequate archived tumor specimen 
for molecular analyses. A total of 231/244 (95%) patients had 
interpretable IHC stains on the TMA and were included for 
analysis. The final cohort had a mean follow‐up of 10.1 years 
(range 0.1‐40 years).
Patient and tumor characteristics are detailed in Table 
1. The majority were adult (n = 212) compared to pediatric 
(≤21 years of age; n = 19). Mean age for adult patients was 
47 years (range 23‐82 years) compared to 16 years (range 
6‐21 years) for pediatric patients. Cervical lymph node dis-
section was done in 49% of cases. Adjuvant I‐131 was given 
to 94% of patients in this study. Tumor size and nodal stage 
were significantly higher in pediatric patients. ATA risk 
groups were represented equally between adult and pediatric 
patients. The majority of patients had intermediate‐ (32%) or 
high‐risk (42%) disease.
3.2 | TMA scoring concordance
Two investigators independently scored the IHC staining on 
the TMAs on a scale from 0 to 3, and their average scores 
for the two to three cores per patient were compared. An av-
erage score greater than or equal to two from at least one 
investigator was considered positive. Concordance in scoring 
between investigators was 72%, 87%, 93%, 85%, and 88% 
for RET, pMEK, MAPK (dpERK), pAKT, and PPARγ, re-
spectively. Cohen’s kappa was 0.46 (95% CI 0.38‐0.54), 0.14 
(95% CI −0.09‐0.37), 0.68 (95% CI 0.57‐0.79), 0.68 (95% 
CI 0.61‐0.75), and 0.63 (95% CI 0.53‐0.73) for RET, pMEK, 
MAPK (dpERK), pAKT, and PPARγ, respectively. pMEK 
staining was positive in 26/184 (14%) of patients, but the 
two investigators only agreed on 6 of the 26 positive scores. 
Cohen’s kappa for MEK crossed zero, and thus, MEK stain-
ing was excluded in further analyses.
3.3 | Association of molecular markers with 
clinicopathologic factors
The overall rate of BRAF V600E mutation in this popula-
tion was 74%, with similar incidence in both adult and 
pediatric patient populations. BRAF V600E mutation was 
significantly enriched in the ATA intermediate‐ (73%) and 
high‐risk (82%) groups compared to low‐risk (61%) patients 
(P = 0.01; Table 2). BRAF V600E mutation was associated 
with clinical stage T3‐4 (OR 2.2, 95% CI 1.2‐4.2), capsular 
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T A B L E  1  Patient and tumor characteristics
Total (n = 231) Adult (n = 212) Pediatric (n = 19) P value
BRAF V600E mutation 170/231 (74%) 156/212 (72%) 14/19 (74%) 1.00
Positive pAKT IHC 83/212 (39%) 75/194 (39%) 8/18 (44%) 0.62
Positive MAPK IHC 29/206 (14%) 28/188 (15%) 1/18 (6%) 0.48
Positive RET IHC 124/205 (61%) 120/189 (64%) 4/16 (25%) 0.006
Positive PPARγ IHC 53/194 (27%) 50/177 (28%) 3/17 (18%) 0.57
Male 65 (28%) 61 (29%) 4 (21%) 0.60
Female 166 (72%) 151 (71%) 15 (79%)
White 197 (85%) 181 (85%) 16 (84%) 0.18
Black 17 (7%) 17 (8%) 0 (0%)
Asian 13 (6%) 11 (5%) 2 (11%)
Hispanic 4 (2%) 3 (2%) 1 (5%)
Mean age (range) 44 (6‐82) 47 (23‐82) 16 (6‐21) <0.001
Lymph node dissection 116 (50%) 103 (49%) 13 (68%) 0.15
Median Post‐op I‐131 dose (mean, range) 105 (0‐230) 105 (0‐230) 125 (0‐175) 0.49
Mean tumor size (range) 2.03 (0.1‐8.5) 1.99 (0.1‐8.5) 2.45 (0.8‐4.5) 0.10
T1 94 (41%) 91 (43%) 3 (16%) 0.01
T2 45 (20%) 38 (18%) 7 (37%)
T3 23 (10%) 23 (11%) 0 (0%)
T4 68 (29%) 59 (28%) 9 (47%)
N0 116 (50%) 110 (52%) 6 (32%) 0.01
N1a 76 (33%) 71 (34%) 5 (26%)
N1b 38 (17%) 30 (14%) 8 (42%)
M0 220 (96%) 202 (96%) 18 (95%) 0.59
M1 10 (4%) 9 (4%) 1 (5%)
AJCC stage
I 154 (67%) 136 (65%) 18 (95%) 0.02
II 14 (6%) 13 (6%) 1 (5%)
III 54 (24%) 54 (26%) 0 (0%)
IV 7 (3%) 7 (3%) 0 (0%)
Multifocal 112/230 (49%) 108/211 (50%) 9/19 (47%) 1.00
Capsular invasion 134/230 (58%) 123/211 (58%) 11/19 (58%) 1.00
Vascular invasion 34/230 (15%) 27/211 (13%) 7/19 (37%) 0.01
Soft tissue invasion 92/230 (40%) 81/211 (38%) 11/19 (58%) 0.14
Positive margins 85/230 (37%) 75/211 (36%) 10/19 (53%) 0.15
Tumor location
Thyroid only 113 (49%) 107 (50%) 6 (32%) 0.25
Thyroid and neck nodes 107 (46%) 95 (45%) 12 (63%)
Thyroid, nodes, and lung 9 (4%) 8 (4%) 51 (5%)
Thyroid and bone 1 (0.5%) 1 (0.5%) 0 (0%)
Unspecified 1(0.5%) 1 (0.5%) 0 (0%)
ATA 2015 risk group
Low 61 (26%) 56 (26%) 5 (26%) 0.21
Intermediate 74 (32%) 71 (34%) 3 (16%)
High 96 (42%) 85 (40%) 11 (58%)
AJCC, American Joint Committee on Cancer; ATA, American Thyroid Association; IHC, immunohistochemistry.
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invasion (OR 2.0, 95% CI 1.1‐3.6), and soft tissue invasion 
(OR 2.3, 95% CI 1.2‐4.4). BRAF V600E mutation was in-
versely linked to MAPK (dpERK) IHC intensity (OR 0.43, 
95% CI 0.19‐0.97), but was not associated with other molecu-
lar markers (Supplemental Table S1).
The overall rate of positive RET staining was 61%. 
Pediatric patients had significantly lower rates of positive 
RET staining compared to adults (25% vs 64%, P = 0.002). 
Males also were less likely to have tumors staining positive 
for RET (OR 0.39, 95% CI 0.21‐0.72). There was no dif-
ference in RET staining among the ATA risk groups. RET 
staining did not have any association with BRAF V600E mu-
tation, but was positively associated with pAKT and PPARγ 
(Supplemental Table S1).
The rates of pAKT, MAPK (dpERK), and PPARγ posi-
tive staining were 39%, 14%, and 27%, respectively. There 
were no significant differences between adult and pediatric 
patients. PPARγ positive staining was less likely in the ATA 
high‐risk group (Table 2). PPARγ positive tumors were less 
likely to be T3‐4 clinical stage (OR 0.75, 95% CI 0.58‐0.97), 
lymph node positive (OR 0.38, 95% CI 0.20‐0.74), multifo-
cal (OR 0.44, 95% CI 0.23‐0.85), and less likely to have soft 
tissue invasion (OR 0.41, 95% CI 0.21‐0.83), or positive mar-
gins (OR 0.35, 95% CI 0.17‐0.73). pAKT, MAPK (dpERK), 
and PPARγ co‐expression was common (Supplemental Table 
S1).
3.4 | Recurrence and cancer‐
specific mortality
Recurrence occurred in 34/231 (14.7%) of cPTC patients dur-
ing a mean of 10 years of follow‐up. Of these, 3 (9%) re-
curred in the thyroid bed alone, 23 (67%) recurred in neck 
lymph nodes, 4 (12%) recurred in distant sites, and 4 (12%) 
patients never achieved remission from distant disease since 
their initial surgery. Rates of recurrence in the ATA low‐, 
intermediate‐, and high‐risk groups were 5%, 10%, and 25%, 
respectively (P = 0.001). There was no significant differ-
ence in recurrence between ATA low‐ and intermediate‐risk 
groups (Table 3). However, the estimated 10‐year FFR was 
significantly worse in the ATA high‐risk group compared 
to the pooled low‐ and intermediate‐risk groups in Kaplan‐
Meier analysis (74% vs 95%, P < 0.001, Figure 1A). RET 
expression was inversely associated with recurrence (HR 
0.46, 95% CI 0.22‐0.96). No other molecular markers were 
independently associated with recurrence in this patient pop-
ulation (Table 3).
There were 9/231 (3.9%) deaths attributed to thyroid can-
cer. Rates of cancer‐specific death in the ATA low‐, inter-
mediate‐, and high‐risk groups were 0%, 1.4%, and 8.3%, 
respectively (P = 0.01). Cancer‐specific death was signifi-
cantly associated with older age, higher T stage, metastatic 
disease, vascular invasion, soft tissue invasion, and positive 
margins (Table 3). No single molecular marker was inde-
pendently associated with cancer‐specific death.
3.5 | Molecular recursive 
partitioning analysis
In exploratory analysis, we sought to identify a molecu-
lar signature that independently predicts a high risk of re-
currence. RET, the only marker independently associated 
with recurrence, was chosen as the initial branch point of 
a recursive partitioning tree. The other molecular markers 
(BRAF, MAPK (dpERK), pAKT, PPARγ) were tested as 
branch points to enrich for a “molecular high‐risk group” 
(Supplemental Figure S1). BRAF V600E mutation did not 
meet significance as a branch point in any iteration of the 
RPA. The final model is depicted in Figure 2. Positive 
RET staining was associated with a low risk of recurrence 
(10%). Patients whose tumors had negative RET staining 
and either positive pAKT or MAPK (dpERK) staining had 
a high risk of recurrence (42%). Patients whose tumors 
were negative for RET, pAKT, and MAPK (dpERK) had a 
16% risk of recurrence and were grouped with the patients 
whose tumors stained positive for RET as part of a “mo-
lecular low‐risk group.” The estimated 10‐year freedom 
from recurrence was significantly lower in the molecular 
high‐risk group compared to the molecular low‐risk group 
(57% vs 90%, P < 0.001, Figure 2B). Incidence of can-
cer‐specific death in the molecular low‐risk and molecular 
high‐risk groups was 3% and 13%, respectively (P = 0.03).
T A B L E  2  Molecular marker expression in ATA low‐, intermediate‐, and high‐risk groups
ATA low risk (%)
ATA intermediate risk 
(%) ATA high risk (%) P value
BRAF V600E mutation 37/61 (61) 54/74 (73) 79/96 (82) 0.01
Positive pAKT IHC 23/56 (41) 29/67 (43) 31/89 (35) 0.54
Positive MAPK IHC 9/53 (17) 10/64 (16) 10/89 (11) 0.58
Positive RET IHC 34/55 (62) 40/64 (63) 50/86 (58) 0.86
Positive PPARγ IHC 19/51 (37) 19/60 (32) 15/83 (18) 0.03
ATA, American Thyroid Association; IHC, immunohistochemistry.
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Incidence of both BRAF mutation and PPARγ expres-
sion was not different between the low‐risk and high‐risk 
molecular score groups (BRAF: 73% vs 75%, respectively, 
P = 0.82; PPARγ: 27% vs 30%, respectively, P = 0.70). The 
presence of BRAF V600E mutation was not associated with 
risk of recurrence in either the molecular low‐risk (log‐rank 
P = 0.34) or high‐risk groups (log‐rank P = 0.16).
3.6 | Comparison of ATA risk and 
molecular score risk
The molecular high‐risk profile was found in 9%, 14%, and 
13% of ATA low‐, intermediate‐, and high‐risk groups, 
respectively (P = 0.77), suggesting the prognostic infor-
mation gained from each of the two risk stratifications is 
unique. In a multivariable model, recurrence was indepen-
dently associated with both ATA high risk (HR = 2.8, 95% 
CI 1.3‐6.0, P = 0.008) and the molecular high‐risk signa-
ture (HR = 5.4, 95% CI 2.5‐12, P < 0.001). Cancer‐specific 
death was also independently associated with both ATA high 
risk (HR = 9.3, 95% CI 1.1‐76, P = 0.04) and the molecular 
high‐risk signature (HR = 4.3, 95% CI 1.0‐18, P = 0.05). 
The 5‐year estimated FFR in ATA low‐/intermediate‐risk 
patients stratified by molecular risk was 99% (molecular 
low risk) vs 64% (molecular high risk), P < 0.001 (Figure 
1C). The 5‐year estimated FFR in ATA high‐risk patients 
Recurrence (Hazard ratio, 95% 
CI) n = 34/231
Cancer death (Hazard 
ratio, 95% CI) n = 9/231
BRAF V600E mutation 1.56 (0.68‐3.59) 3.48 (0.43‐27.9)
Positive pAKT IHC 1.09 (0.53‐2.25) 0.60 (0.12‐2.95)
Positive MAPK IHC 1.57 (0.65‐3.84) 0.71 (0.09‐5.70)
Positive RET IHC 0.46 (0.22‐0.96) 0.45 (0.11‐1.91)
Positive PPARγ IHC 0.37 (0.11‐1.23) 1.01 (0.21‐4.93)
Molecular high‐risk score 5.57 (2.56‐12.1) 4.73 (1.12‐19.9)
Age 1.00 (0.98‐1.03) 1.05 (1.01‐1.10)
Male vs female 1.47 (0.72‐2.97) 1.96 (0.52‐7.30)
Race
White (Ref) Ref Ref
Black 0.38 (0.05‐2.82) Unable to calculate HRb
Asian 0.99 (0.23‐4.20) 1.85 (0.23‐14.9)
Hispanic 2.03 (0.28‐14.9) Unable to calculate HRb
Tumor size 1.37 (1.18‐1.59) 1.28 (0.95‐1.73)
T3‐4 vs T1‐2 3.10 (1.54‐6.28) 12.3 (1.53‐98.3)
Node positive 5.25 (2.17‐12.7) 7.85 (0.98‐62.8)
M1 vs M0 7.47 (2.85‐19.6) 16.1 (3.82‐67.8)
AJCC stage
III‐IV vs I‐II 3.42 (1.74‐6.72) 26.3 (3.26‐211)
Multifocal 2.29 (1.10‐4.76) 7.80 (0.96‐63.6)
Capsular invasion 3.06 (1.33‐7.07) Unable to calculate HRc
Vascular invasion 5.02 (2.48‐10.2) 5.26 (1.31‐21.2)
Soft tissue invasion 3.37 (1.63‐6.95) 10.9 (1.34‐88.9)
Positive margins 2.59 (1.30‐5.18) 12.4 (1.52‐101)
First I‐131 dose 1.00 (0.99‐1.01) 1.01 (0.99‐1.03)
ATA risk
Low Ref Ref
Intermediate 2.01 (0.52‐7.77) Unable to calculate HRc
High 5.90 (1.78‐19.6) Unable to calculate HRc
aBolded text signified the table variable was statistically significant. 
AJCC, American Joint Committee on Cancer; ATA, American Thyroid Association; IHC, immunohistochemis-
try; Ref, reference variable.
bNo cancer death in patient group. 
cNo cancer death in reference group. 
T A B L E  3  Univariable analyses of 
recurrence and cancer‐specific death and 
their associations with molecular and 
clinicopathologic factors. Hazard ratios and 
95% confidence intervals (CI) are noted for 
recurrence and cancer‐specific death
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stratified by molecular risk was 83% (molecular low risk) vs 
47% (molecular high risk), P < 0.001 (Figure 1C).
4 |  DISCUSSION
This large retrospective study of cPTC patients at a single in-
stitution characterized the expression of factors upstream and 
downstream along the BRAF/MAPK/ERK and RAS/pAKT 
pathways. We observed differences in RET tumor stain-
ing between adult and pediatric patients, and differences in 
BRAF V600E mutation between ATA risk groups. Clinical 
follow‐up of up to 20 years in this cohort allowed adequate 
time for recurrences and cancer‐specific survival to be as-
sessed. As expected, recurrence was more likely in the ATA 
high‐risk group (25%). Only 5% and 10% of the ATA low‐ 
and intermediate‐risk patients recurred, respectively, which 
is comparable to prior reports.3 With the exception of RET 
expression, the molecular markers individually did not as-
sociate with recurrence risk. However, a proposed molecular 
risk stratification was identified from recursive partitioning 
analysis of multiple molecular markers. Patients whose tu-
mors displayed the molecular high‐risk group of RET‐nega-
tive and either pAKT‐positive or MAPK (dpERK)‐positive 
IHC had quadruple the risk of recurrence compared to the 
low‐risk group. The molecular risk score also assigned risk of 
recurrence independent of classic pathologic findings, sug-
gesting molecular subtypes of cPTCs may explain some of 
the heterogeneity seen in outcomes based on the 2015 ATA 
risk classification system.
F I G U R E  1  Kaplan‐Meier analysis for freedom from recurrence (FFR). A, FFR of patients stratified by ATA risk groups, B, FFR of patients 
stratified by a proposed molecular score. C, FFR of patients stratified by both ATA risk groups and a proposed molecular score
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This study incorporates immunohistochemical staining of 
multiple molecular markers, including RET, into a prognostic 
score for disease recurrence in cPTCs ranging from ATA low 
to high risk. Prior efforts to incorporate molecular prognos-
tics have focused on tumor genetic mutations. Genetic panels 
are being developed to differentiate benign from malignant 
thyroid nodules.11 Niemeier et al created a model utilizing 
BRAF mutation and clinicopathologic factors for predicting 
extrathyroid tumor spread in papillary microcarcinomas.12 
Most recently, a mutation in the telomerase reverse transcrip-
tase (TERT) promoter with or without a concomitant BRAF 
V600E mutation was found to be associated with recurrence 
and cancer death risk.13,14 Several other prognostic score algo-
rithms have been suggested, but these have not incorporated 
molecular analysis of tumors.15 An advantage of IHC over 
genetic analysis alone is that translated protein products and 
post‐translational regulatory modifications such as activating 
phosphorylation of kinases can be qualitatively assessed.
Similar to our prior report,7 in this cohort, BRAF V600E 
mutation was not associated with recurrence or death. 
Rather, MAPK (dpERK) staining in the absence of RET 
staining was highly associated with recurrence and death. 
MAPK (dpERK)/ERK is a kinase activated downstream of 
both the BRAF and RAS pathways, and participates in pro-
liferation and dedifferentiation.16 Intriguingly, positive IHC 
staining of MAPK (dpERK) in BRAF mutant tumors was 
half as likely as in BRAF wild‐type tumors in this study. 
Activated pMEK staining was also significantly lower 
(14%) in this population than the percentage of BRAF mu-
tants (74%) would suggest. This finding has been observed 
in human PTC samples17 as well as in melanoma, atypical 
nevi, and common nevi.18 Zuo et al showed in 42 human 
papillary thyroid cancer samples that only 7.1% of PTCs 
with BRAF mutation had activated MAPK (dpERK)/ERK. 
In contrast, 29% of wild‐type BRAF PTCs had activated 
MAPK (dpERK). In their cohort, BRAF V600E mutation 
was not associated with any negative clinicopathologic 
factors except for age >45 years.17 These data corroborate 
findings in a large 459 patient study from the University of 
California, San Francisco, in which BRAF V600E mutation 
was also not associated with negative clinicopathologic fac-
tors.19 In a recent publication, BRAF V600E mutation did 
not worsen cancer‐specific mortality in patients <45 years 
old.20 Thus, the association of BRAF V600E mutation with 
aggressive PTC pathology and clinical recurrence remains 
unclear. The lack of association between BRAF mutation 
and MAPK (dpERK) activation at the protein level in PTCs 
could partially explain this discrepancy.
In this study, patients with RET positive tumor staining 
alone were half as likely to experience recurrence compared 
to patients with RET‐negative tumors. In contrast, a meta‐
analysis of eight studies with 1000 patients found RET am-
plification through rearrangement was associated with twice 
the risk of distant metastasis.14 RET rearrangement involving 
the C‐terminus tyrosine kinase domain of the protein results 
in constitutive activation, and these fusion proteins are de-
tected by the C‐terminal specific antibodies commonly used 
for IHC, including the one used in this study.21,22 However, 
the downstream phenotype of RET rearrangement depends 
on the specific N‐terminal fusion partner. The RET/PTC3 re-
arrangement, mostly found in tumors from patients with prior 
radiation exposure,23,24 is associated with aggressive features 
such as larger tumor size, extrathyroidal extension, and nodal 
metastases. On the other hand, RET rearrangements in most 
sporadic PTCs are the RET/PTC1 rearrangement. These 
well‐differentiated PTCs rarely dedifferentiate and tend to 
have a more indolent course.21,22 Therefore, in patients with-
out prior radiation exposure, RET activation alone appears 
to be a positive prognostic biomarker. This study is limited 
since we did not test for RET gene rearrangement subtype, 
but only 7 (3%) patients were known to have had prior neck 
radiation exposure.
F I G U R E  2  Recursive partitioning 
analysis of molecular markers and 
recurrence risk (RR). RET, pAKT, MAPK, 
BRAF, and PPARγ were included in the 
initial model, and the tree was pruned 
manually
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How RET rearrangement might abrogate the downstream 
effects of MAPK (dpERK)‐ or pAKT‐expressing tumors re-
mains to be elucidated. In our population, 13% and 49% of 
samples staining positive for RET overexpressed MAPK 
(dpERK) and pAKT, respectively. Despite activation of the 
traditional BRAF/MAPK (dpERK) and RAS/pAKT pathways, 
these tumors behaved indolently, with only a 10% recurrence 
rate in our cohort. RET kinase activity may be important in 
maintaining differentiation through micro‐ribonucleic acid 
(miRNA) regulation. Prior work has shown the importance of 
miRNA in silencing target genes.25 RET mutations upregulate 
the biogenesis of miRNAs,26 and emerging work has identi-
fied miR30a as important in maintaining PTC differentiation 
through the inhibition of lysyl oxidase.27,28 In addition, pAKT 
localization has been shown to be dependent on the presence 
of RET rearrangement.29 In non‐invasive areas of PTC co‐ex-
pressing RET, pAKT expression was diffuse and cytoplasmic. 
This was in contrast to invasive areas of PTC without RET co‐
expression, where pAKT expression was focal and localized 
in the nucleus.29 pAKT expression in our cohort was predom-
inantly localized in the nucleus, independent of RET staining. 
As 50% of the PTC patients in the previous work by Vasko et 
al29 were exposed to the Chernobyl radiation accident, differ-
ences in the specific RET rearrangement (eg, RET/PTC1 vs 
RET/PTC3) may account for this discrepancy. Further work is 
needed to study these post‐translational interactions.
Limitations of this single institution study include the retro-
spective bias of patient selection/referral patterns. By omitting 
patients not referred for adjuvant RAI, the results are poten-
tially skewed to higher risk patients. However, patients in this 
cohort were treated with consistent institutional guidelines and 
most had long‐term follow‐up. Second, the selection of tested 
molecular markers in this study was decided before the TCGA 
analysis was published, and RAS and TERT mutations were 
not evaluated. These should be taken into account in follow‐up 
studies. Third, sampling effect and tumor heterogeneity can 
complicate TMA analysis of potential biomarkers, but tripli-
cate cores and multi‐investigator blinded analysis are known 
to maximize consistency.30 Fourth, the evaluation of phos-
phorylated proteins by immunohistochemistry is dependent on 
time to tissue fixation and other conditions ex vivo which may 
change the phosphorylation state of the sample.31,32 Finally, 
the proposed molecular risk score was derived statistically 
from recursive partitioning analysis and is only hypothesis‐
generating. Further mechanistic work should be supported, and 
prognostic scores need to be validated.
5 |  CONCLUSIONS
In this exploratory analysis, positive RET staining by IHC 
was associated with a low risk of recurrence and death from 
papillary thyroid cancer. In patients with RET‐negative 
tumors, positive pAKT or MAPK (dpERK) staining con-
stituted a high molecular risk subgroup of tumors. IHC 
analysis of molecular biomarkers may assist clinicians in 
further stratifying risk of recurrence when combined with 
the current ATA risk classifications.
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